Inhibin α-subunit (inha) Gene And Locus Changes In Paediatric Adrenocortical Tumours From Tp53 R337h Mutation Heterozygote Carriers

The R337H TP53 mutation is a low-penetrance molecular defect that predisposes to adrenocortical tumour (ACT) formation in Brazilian and possibly other populations. Additional genetic defects may be responsible for the variable expression of ACTs m these cases. The inhibin α-subunit gene (INHA) on 2q33-qter has been implicated in mouse adrenocortical tumourigenesis. We studied 46 pediatric patients with ACTs from Brazil for INHA genetic alterations; 39 of these patients were heterozygous carriers of the R337H TP53 mutation. We first mapped the INHA gene by radiation hybrid analysis and determined 10 linked microsatellite markers in an area flanked by D2S1371 and D2S206 on 2q33-qter. These markers were then used for loss of heterozygozity (LOH) studies in nine paired germline and tumour DNA samples. Mapping placed the INHA gene in close proximity to D2S2848 (SHGC11864) with a log of odds (LOD) score of 5.84. LOH for at least one marker in the region was identified in 8/9 tumours (89%). Six patients were heterozygous for three INHA mutations: one in exon 1, 127C>G, and two in exon 2,3998G>A and 4088G>A, all leading to amino acid substitutions (P43A, G227R, and A257T, respectively). A257T is located in a conserved INHA region, highly homologous to transforming growth factor-β; both G227R and A257T change polarity, and, in addition, G227R changes the pH. We conclude that these sequence alterations and the detected 2q allelic changes suggest that INHA may be one of the contributing factors needed for ACT formation in pediatric patient carriers of the R337H TP53 mutation.415354359Stratakis, C.A., Genetics of adrenocortical tumors: Gatekeepers, landscapers and conductors in symphony (2003) Trends Endocrinol Metab, 14, pp. 404-410Ribeiro, R.C., Sondrini, F., Figueiredo, B., Zambetti, G.P., Michalkiewicz, E., Lafferty, A.R., Delzcerda, L., Sandrini, R., An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma (2001) Proc Natl Acad Sci U S A, 98, pp. 9330-9335Latronico, A.C., Pinto, E.M., Domenice, S., Fragoso, M.C., Martin, R.M., Zerbini, M.C., Lucon, A.M., Mendonca, B.B., An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors (2001) J Clin Endocrinol Metab, 86, pp. 4970-4973Varley, J.M., McGown, G., Thorncroft, M., Jomes, L.A., Margison, G.P., Forster, G., Evans, D.G., Birch, J.M., Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors (1999) Am J Hum Genet, 65, pp. 995-1006DiGiammarino, E.L., Lee, A.S., Cadwell, C., Zhang, W., Bothner, B., Ribeiro, R.C., Zambetti, G., Kriwacki, R.W., A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer (2002) Nat Struct Biol, 9, pp. 12-16Hainaut, P., Tumor-specific mutations in p53: The acid test (2002) Nat Med, 8, pp. 21-23Figueiredo, B.C., Stratakis, C.A., Sandrini, R., Delacerda, L., Pionovsky, M.A., Giatzakis, C., Young, H.M., Haddad, B.R., Comparative genomic hybridization analysis of adrenocortical tumors of childhood (1999) J Clin Endocrinol Metab, 84, pp. 1116-1121James, L.A., Kelsey, A.M., Birch, J.M., Varley, J.M., Highly consistent genetic alterations in childhood adrenocortical tumours detected by comparative genamic hybridization (1999) Br J Cancer, 81, pp. 300-304Sidhu, S., Marsh, D.J., Theodosopoulos, G., Philips, J., Bambach, C.P., Campbell, P., Magarey, C.J., Robinson, B.G., Comparative genomic hybridization analysis of adrenocortical tumors (2002) J Clin Endocrinol Metab, 87, pp. 3467-3474Logie, A., Boulle, N., Gaston, V., Perin, L., Boudou, P., Le Bouc, Y., Gicquel, C., Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCl H295R cell line (1999) J Mol Endocrinol, 23, pp. 23-32Wilkin, F., Gagne, N., Paquette, J., Oligny, L.L., Deal, C., Pediatric adrenocortical tumors: Molecular events leading to insulin-like growth factor II gene overexpression (2000) J Clin Endocrinol Metab, 85, pp. 2048-2056Cherradi, N., Bideau, M., Arnaudeau, S., Demaurex, N., James, R.W., Azhar, S., Capponi, A.M., Angiotensin II promotes selective uptake of high density lipoprotein cholesterol esters in bovine adrenal glomeruloso and human adrenocortical carcinoma cells through induction of scavenger receptor class B type I (2001) Endocrinology, 142, pp. 4540-4549Takahashi, K., Yoshinoya, A., Murokami, O., Totsune, K., Shibahara, S., Production and secretion of two vasoactive peptides, adrenomedullin and endothelin-1, by cultured human adrenocortical carcinoma cells (2000) Peptides, 21, pp. 251-256Takahashi, K., Totsune, K., Murakami, O., Shibahara, S., Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells (2001) Peptides, 22, pp. 1175-1179Martinerie, C., Gicquel, C., Loyvel, A., Laurent, M., Schofield, P.N., Le Bouc, Y., Altered expression of novH is associated with human adrenocortical tumorigenesis (2001) J Clin Endocrinol Metab, 86, pp. 3929-3940Peri, A., Luciani, P., Conforti, B., Boglioni-Peri, S., Cioppi, F., Crescioli, C., Ferruzzi, P., Mannelli, M., Variable expression of the transcription factors cAMP response element-binding protein and inducible cAMP early repressor in the normal adrenal cortex and in adrenocortical adenomas and carcinomas (2001) J Clin Endocrinol Metab, 86, pp. 5443-5449Risbridger, G.P., Schmitt, J.F., Robertson, D.M., Activins and inhibins in endocrine and other tumors (2001) Endocr Rev, 22, pp. 830-858Mason, A.J., Hayflick, J.S., Ling, N., Esch, F., Ueno, N., Ying, S.Y., Guillemin, R., Seeburg, P.H., Complementary DNA sequences of ovarian follicular fluid inhibin show precursor structure and hamology with transforming growth factor-β (1985) Nature (London), 318, pp. 659-663Mason, A.J., Niall, H.D., Seeburg, P.H., Structure of two human ovarian inhibins (1986) Biochem Biophys Res Commun, 133, pp. 957-964Barton, D.E., Yang-Feng, T.L., Mason, A.J., Seeburg, P.H., Francke, U., Mapping of genes for inhibin subunits α, βA, and βB on human and mouse chromosomes and studies of jsd mice (1989) Genomics, 5, pp. 91-99Matzuk, M.M., Finegold, M.J., Mother, J.P., Krummen, L., Lu, H., Bradley, A., Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice (1994) Proc Natl Acad Sci U S A, 91, pp. 8817-8821McCluggage, W.G., Burton, J., Maxwell, P., Sloan, J.M., Immunohistochemical staining of normal, hyperplastic, and neaplastic adrenal cortex with a monoclonal antibody against alpha inhibin (1998) J Clin Pathol, 51, pp. 114-116Vanttinen, T., Kuulasmaa, T., Liu, J., Voutilainen, R., Expression of activin/inhibin receptor and binding protein genes and regulation of activin/inhibin peptide secretion in human adrenocortical cells (2002) J Clin Endocrinol Metab, 87, pp. 4257-4263Vanttinen, T., Liu, J., Kuulasmaa, T., Kivinen, P., Voutilainen, R., Expression of activin/inhibin signaling components in the human adrenal gland and the effects of activins and inhibins on adrenocorticol steroidogenesis and apoptasis (2003) J Endocrinol, 178, pp. 479-489Stratakis, C.A., Taymans, S.E., Daruwala, R., Song, J., Levine, M., Mapping of the human genes (SLC23A2 and SLC23A1) coding for vitamin C transporters 1 and 2 (SVCT1 and SVCT2) ta 5q23 and 20p12, respectively (2000) J Med Genet, 37, pp. E20Stratakis, C.A., Jenkins, R.B., Pros, E., Mitsiadis, C.S., Raff, S.B., Stalboerger, P.G., Tsigos, C., Chrousos, G.P., Cytogenetic and microsatellite alterations in tumors from patients with the syndrome of myxomas, spotty skin pigmentation, and endocrine overactivity (Carney complex) (1996) J Clin Endocrinol Metab, 81, pp. 3607-3614Cox, D.R., Burmeister, M., Price, E.R., Kim, S., Meyers, R.M., Radiation hybrid mapping: A somatic cell technique for constructing high resolution maps of mammalian chromosomes (1990) Science, 250, pp. 245-250Spur, N.K., Bashir, R., Bushby, K., Cox, A., Cox, S., Hilde Brandt, F., Hill, N., Naylor, S., Report and abstracts of the Fourth International Workshop on Human Chromosome 2 Mapping 1996 (1996) Cytogenet Cell Genet, 73, pp. 255-273Taymans, S.E., Kirschner, L.S., Giotzakis, C., Stratakis, C.A., Radiation hybrid mopping of chromosomal region 2p15-p16: Integration of expressed and polymorphic sequences maps at the Carney complex (CNC) and Doyne honeycamb retinal dystrophy (DHRD) loci (1999) Genomics, 56, pp. 344-349Xu, J., McKeehan, K., Matsuzaki, K., McKeehan, W.L., Inhibin antagonizes inhibition of liver cell growth by activin by a dominant-negative mechanism (1995) J Biol Chem, 270, pp. 6308-6313Martens, J.W., De Winter, J.P., Timmerman, M.A., McLuskey, A., Van Schaik, R.H., Themmen, A.P., De Jong, F.H., Inhibin interferes with activin signalling at the level of the activin receptor complex in Chinese hamster ovary cell (1997) Endocrinology, 138, pp. 2928-2936Lewis, K.A., Gray, P.C., Blount, A.L., MacConell, L.A., Wiater, E., Bilezikjian, L.M., Vale, W., Betaglycan binds inhibin and can mediate functional antagonism of activin signalling (2000) Nature, 404, pp. 411-414Stratakis, C.A., Chrousos, G.P., Adrenal cancer (2000) Endocrinol Metab Clin North Am, 29, pp. 15-25Watson, R.H., Roy Jr., W.J., Davis, M., Hitchcock, A., Campbell, I.G., Loss of heterozygosity at the alpha-inhibin locus on chromosome 2q is not a feature or human granulosa cell tumors (1997) Gynecol Oncol, 65, pp. 387-390Dowling, C.R., Risbridger, G.P., The role of inhibins and activins in prostate cancer pathogenesis (2000) Endocr Relat Cancer, 7, pp. 243-256Zhao, J., Speel, E.J., Muletta-Feurer, S., Rutimann, K., Saremaslani, P., Roth, J., Heitz, P.U., Komminoth, P., Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis (1999) Am J Pathol, 155, pp. 1039-104